Ecaterina Ileana Dumbrava

20PUBLICATIONS
169CO-AUTHORS
Tumour immunologyMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Sep 07, 2026
Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors.

|Mar 26, 2026
Comprehensive Genomic and Transcriptomic Analysis to Guide Therapy for Patients with Metastatic Solid Tumors.

Burak Uzunparmak, Fei Su, Amber Johnson

|Mar 04, 2026
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors.

Alison M Schram, John J Park, Antoine Italiano

|Jan 06, 2026
The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology.

Amber Johnson, Yifei Shen, Xiaofeng Zheng

|Nov 24, 2025
Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach.

Taiwo Adesoye, Ecaterina E Dumbrava, Kanwal P S Raghav

|Aug 27, 2025
Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit.

Camila Braganca Xavier, Clark R Andersen, JoAnn Lim

Pageof 4

Frequent Collaborators

11 joint publications

Funda Meric-Bernstam

8 joint publications

Jordi Rodon Ahnert

6 joint publications

Sarina A Piha-Paul

6 joint publications

Siqing Fu